Roche will have to wait on its big MS drug application; Pfizer ties up with BioInvent on new antibodies for cancer
Roche’s pioneering MS drug Ocrevus (ocrelizumab) has hit a snag at the FDA. Billed as one of the biggest potential blockbusters in the pipeline …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
